BCM
DVAX

BlueCrest Capital Management’s Dynavax Technologies DVAX Stock Holding History

BlueCrest Capital Management’s Portfolio DVAX Stock Details DVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,729
Closed -$145K – 1004
2018
Q3 		$145K Buy
+11,729
New +$159K ﹤0.01% 1339

Other funds holding DVAX

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

BlueCrest Capital Management's DVAX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Dynavax Technologies (DVAX) in Q4 2018, closing a stake of 11,729 shares — an estimated $145K sold.

BlueCrest Capital Management first reported a position in DVAX in Q3 2018 and held it in 1 quarter. The position peaked at $145K in Q3 2018. 132 funds tracked by Wall St. Rank hold DVAX as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Dynavax Technologies position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,729 Dynavax Technologies shares in Q4 2018, an estimated $145K.
  • BlueCrest Capital Management first reported a position in Dynavax Technologies in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Dynavax Technologies position peaked at $145K in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Dynavax Technologies as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.